| Record Information |
| Version |
3.5 |
| Creation Date |
2005-11-16 08:48:42 -0700 |
| Update Date |
2013-02-08 17:08:12 -0700 |
| HMDB ID |
HMDB00267 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
| Common Name |
Pyroglutamic acid |
| Description |
Pyroglutamic acid is a cyclized derivative of L-glutamic acid. It is an uncommon amino acid derivative in which the free amino group of glutamic acid cyclizes to form a lactam. It is formed nonenzymatically from glutamate, glutamine, and gamma-glutamylated peptides, but it can also be produced by the action of gamma-glutamylcyclotransferase on an L-amino acid. Elevated blood levels may be associated with problems of glutamine or glutathione metabolism. This compound is found in substantial amounts in brain tissue and other tissue in bound form, especially skin. Also present in plant tissues. It is sold, over the counter, as a "smart drug" for improving blood circulation in the brain. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- (-)-2-Pyrrolidone-5-carboxylate
- (-)-2-Pyrrolidone-5-carboxylic acid
- (-)-Pyroglutamate
- (-)-Pyroglutamic acid
- (5S)-2-Oxopyrrolidine-5-carboxylate
- (5S)-2-Oxopyrrolidine-5-carboxylic acid
- (S)-(-)-2-Pyrrolidone-5-carboxylate
- (S)-(-)-2-Pyrrolidone-5-carboxylic acid
- (S)-(-)-g-Butyrolactam-g-carboxylate
- (S)-(-)-g-Butyrolactam-g-carboxylic acid
- (S)-(-)-gamma-Butyrolactam-gamma-carboxylate
- (S)-(-)-gamma-Butyrolactam-gamma-carboxylic acid
- (S)-2-Pyrrolidone-5-carboxylate
- (S)-2-Pyrrolidone-5-carboxylic acid
- (S)-5-Oxo-2-pyrrolidinecarboxylate
- (S)-5-Oxo-2-pyrrolidinecarboxylic acid
- (S)-Pyroglutamate
- (S)-Pyroglutamic acid
- 2-L-Pyrrolidone-5-carboxylate
- 2-L-Pyrrolidone-5-carboxylic acid
- 2-Oxopyrrolidine-5(S)-carboxylate
- 2-Oxopyrrolidine-5(S)-carboxylic acid
- 2-Pyrrolidinone-5-carboxylate
- 2-Pyrrolidinone-5-carboxylic acid
- 5-Carboxy-2-pyrrolidinone
- 5-L-Oxoproline
- 5-Oxo-L-proline
- 5-Oxoproline
- 5-Pyrrolidinone-2-carboxylate
- 5-Pyrrolidinone-2-carboxylic acid
- Ajidew A 100
- Glutimate
- Glutimic acid
- Glutiminate
- Glutiminic acid
- L-2-Pyrrolidone-5-carboxylate
- L-2-Pyrrolidone-5-carboxylic acid
- L-5-Carboxy-2-pyrrolidinone
- L-5-Oxo-2-pyrrolidinecarboxylate
- L-5-Oxo-2-pyrrolidinecarboxylic acid
- L-5-Oxoproline
- L-Glutamic acid g-lactam
- L-Glutimate
- L-Glutimic acid
- L-Glutiminate
- L-Glutiminic acid
- L-Pyroglutamate
- L-Pyroglutamic acid
- L-Pyrrolidinonecarboxylate
- L-Pyrrolidinonecarboxylic acid
- L-Pyrrolidonecarboxylate
- L-Pyrrolidonecarboxylic acid
- Oxoproline
- Oxopyrrolidinecarboxylate
- Oxopyrrolidinecarboxylic acid
- Pidolate
- Pidolic acid
- Pidolidone
- Pyroglutamate
- Pyroglutamic acid
- Pyrrolidinonecarboxylate
- Pyrrolidinonecarboxylic acid
- Pyrrolidone-5-carboxylate
- Pyrrolidone-5-carboxylic acid
- Pyrrolidonecarboxylic acid
|
| Chemical Formula |
C5H7NO3 |
| Average Molecular Weight |
129.114 |
| Monoisotopic Molecular Weight |
129.042593095 |
| IUPAC Name |
(2S)-5-oxopyrrolidine-2-carboxylic acid |
| Traditional IUPAC Name |
pyroglutamic acid |
| CAS Registry Number |
98-79-3 |
| SMILES |
OC(=O)[C@@H]1CCC(=O)N1 |
| InChI Identifier |
InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1 |
| InChI Key |
ODHCTXKNWHHXJC-VKHMYHEASA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Aliphatic Heteromonocyclic Compounds |
| Class |
Pyrrolidines |
| Sub Class |
Pyrrolidine Carboxylic Acids and Derivatives |
| Other Descriptors |
- 5-oxoproline(ChEBI)
- Aliphatic Heteromonocyclic Compounds
- Other amino acids(KEGG)
- Oxoprolines
|
| Substituents |
- Carboxamide Group
- Carboxylic Acid
- Lactam
- Pyrrolidone
- Secondary Carboxylic Acid Amide
|
| Direct Parent |
Pyrrolidine Carboxylic Acids and Derivatives |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Component of Glutathione metabolism
- Essential amino acid
|
| Application |
Not Available |
| Cellular locations |
- Cytoplasm (predicted from logP)
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
476.0 mg/mL at 13 °C |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
| Gas-MS Spectrum |
| 1H NMR Spectrum |
| MS/MS Spectrum Quattro_QQQ 10 |
| MS/MS Spectrum Quattro_QQQ 25 |
| MS/MS Spectrum Quattro_QQQ 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 30 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 40 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 50 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 10 |
| MS/MS Spectrum LC-ESI-QQ (API3000, Applied Biosystems) 20 |
| [1H,13C] 2D NMR Spectrum |
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm (predicted from logP)
|
| Biofluid Locations |
- Blood
- Cerebrospinal Fluid (CSF)
- Urine
|
| Tissue Location |
|
| Pathways |
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
19.5 +/- 3.7 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
47 +/- 30 uM |
Not Specified |
Both |
Normal |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
41.0 +/- 31.0 uM |
Adult (>18 years old) |
Not Specified |
Normal |
Not Available |
| Urine |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Normal |
Urine compound detected by GC-MS
|
| Urine |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
20.7 (10.2-32.6) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
urine by NMR
|
| Urine |
Detected and Quantified |
|
14.0 +/- 7.2 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
7.3 (0.1-29.3) umol/mmol creatinine |
Newborn (0-30 days old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
24.1 (3.4-54.2) umol/mmol creatinine |
Infant (0-1 year old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
5.3 (2.9-10.4) umol/mmol creatinine |
Children (1-13 year old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
3.1 (1.9-11.3) umol/mmol creatinine |
Adolescent (13-18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
18.6(4.5-24.9) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
by GC-MS
|
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
87.00 (13.00-161.00) uM |
Adult (>18 years old) |
Both |
Glutathione synthetase deficiency |
Not Available |
| Blood |
Detected and Quantified |
|
3.5 (3.00-4.00) uM |
Adult (>18 years old) |
Both |
Glutathione synthetase deficiency |
Not Available |
| Cerebrospinal Fluid (CSF) |
Detected and Quantified |
|
2326.0 uM |
Adult (>18 years old) |
Both |
Pyroglutamic aciduria |
Not Available |
| Urine |
Detected and Quantified |
|
28.8 (3.4-54.2) umol/mmol creatinine |
Adult (>18 years old) |
Both |
5-Oxoprolinase deficiency |
Not Available |
| Urine |
Detected and Quantified |
|
3500.0 (1000.0-6000.0) umol/mmol creatinine |
Adult (>18 years old) |
Both |
5-Oxoprolinase Deficiency |
Not Available |
| Urine |
Detected and not Quantified |
|
Not Applicable |
Adult (>18 years old) |
Both |
Autosomal dominant polycystic kidney disease |
Not Available |
| Urine |
Detected and Quantified |
|
17000.00 (4000.00-30000.00) umol/mmol creatinine |
Adult (>18 years old) |
Both |
Glutathione synthetase deficiency |
Not Available |
| Urine |
Detected and Quantified |
|
1.9 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Pyroglutamic aciduria |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Glutathione synthetase deficiency |
- Jellum E, Stokke O, Eldjarn L: Combined use of gas chromatography, mass spectrometry, and computer in diagnosis and studies of metabolic disorders. Clin Chem. 1972 Aug;18(8):800-9.
Pubmed: 4557757
- Wevers RA, Engelke U, Heerschap A: High-resolution 1H-NMR spectroscopy of blood plasma for metabolic studies. Clin Chem. 1994 Jul;40(7 Pt 1):1245-50.
Pubmed: 8013094
- http://www.metagene.de/program/d.prg?mp=GLUTATHIONE%20SYNTHETASE%20DEFICIENCY
|
| 5-oxoprolinase deficiency |
- http://www.metagene.de/program/d.prg?mp=5-OXOPROLINASE%20DEFICIENCY
|
|
| Associated OMIM IDs |
- 266130
(Glutathione synthetase deficiency)
- 260005
(5-oxoprolinase deficiency)
|
| External Links |
| DrugBank ID |
DB03088  |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB014506 |
| KNApSAcK ID |
C00007403  |
| Chemspider ID |
7127  |
| KEGG Compound ID |
C01879  |
| BioCyc ID |
CPD-589  |
| BiGG ID |
1800372  |
| Wikipedia Link |
Pyroglutamic acid  |
| NuGOwiki Link |
HMDB00267  |
| Metagene Link |
HMDB00267  |
| METLIN ID |
3251  |
| PubChem Compound |
7405  |
| PDB ID |
PCA  |
| ChEBI ID |
18183  |
| References |
| Synthesis Reference |
Pumpor, Ksenia; Boettcher, Christoph; Fehn, Susanna; Burger, Klaus. Hexafluoroacetone as protecting and activating reagent: an efficient strategy for activation of pyroglutamic acid and homologs.Heterocycles (2003), 61 259-269. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Manning NJ, Davies NP, Olpin SE, Carpenter KH, Smith MF, Pollitt RJ, Duncan SL, Larsson A, Carlsson B: Prenatal diagnosis of glutathione synthase deficiency. Prenat Diagn. 1994 Jun;14(6):475-8.
Pubmed: 7937585
- Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ: In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol. 2001 Mar;116(3):434-42.
Pubmed: 11231318
- Hussain Z, Lannigan R, Stoakes L: A new approach for presumptive identification of clinically important streptococci. Zentralbl Bakteriol Mikrobiol Hyg [A]. 1984 Oct;258(1):74-9.
Pubmed: 6441390
- Guneral F, Bachmann C: Age-related reference values for urinary organic acids in a healthy Turkish pediatric population. Clin Chem. 1994 Jun;40(6):862-6.
Pubmed: 8087979
- Creer MH, Lau BW, Jones JD, Chan KM: Pyroglutamic acidemia in an adult patient. Clin Chem. 1989 Apr;35(4):684-6.
Pubmed: 2702756
- Hammond JW, Potter M, Truscott R, Wilcken B: gamma-Glutamylglutamine identified in plasma and cerebrospinal fluid from hyperammonaemic patients. Clin Chim Acta. 1990 Dec 24;194(2-3):173-83.
Pubmed: 2093471
- Uhlhaas S, Lange H: Striatal deficiency of L-pyroglutamic acid in Huntington's disease is accompanied by increased plasma levels. Brain Res. 1988 Aug 2;457(1):196-9.
Pubmed: 2971422
- Jellum E, Stokke O, Eldjarn L: Combined use of gas chromatography, mass spectrometry, and computer in diagnosis and studies of metabolic disorders. Clin Chem. 1972 Aug;18(8):800-9.
Pubmed: 4557757
- Croal BL, Glen AC, Kelly CJ, Logan RW: Transient 5-oxoprolinuria (pyroglutamic aciduria) with systemic acidosis in an adult receiving antibiotic therapy. Clin Chem. 1998 Feb;44(2):336-40.
Pubmed: 9474033
- Winslow JW, Shih A, Bourell JH, Weiss G, Reed B, Stults JT, Goldsmith LT: Human seminal relaxin is a product of the same gene as human luteal relaxin. Endocrinology. 1992 May;130(5):2660-8.
Pubmed: 1572287
- Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan WL: Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis. 1993;16(4):648-69.
Pubmed: 8412012
- Wevers RA, Engelke U, Heerschap A: High-resolution 1H-NMR spectroscopy of blood plasma for metabolic studies. Clin Chem. 1994 Jul;40(7 Pt 1):1245-50.
Pubmed: 8013094
- Erasmus E, Mienie LJ, de Vries WN, de Wet WJ, Carlsson B, Larsson A: Prenatal analysis in two suspected cases of glutathione synthetase deficiency. J Inherit Metab Dis. 1993;16(5):837-43.
Pubmed: 8295398
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4.
Pubmed: 19212411
|